Biogen Inc. (NASDAQ: BIIB) announced it expects to record approximately $34 million in acquired in-process research and development, upfront and milestone expenses on a pre-tax basis during the first quarter of 2026.

The charge is projected to impact both GAAP and non-GAAP net income per diluted share by approximately $0.19 per share for the quarter, according to a company statement.

The expenses include costs related to collaboration and license agreements, upfront and milestone payments, and when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development.

Biogen stated it does not typically forecast such expenses due to uncertainty regarding the timing, occurrence and magnitude of these transactions in any given period.

The company noted that results for the quarter ended March 31, 2026, have not been finalized and remain subject to financial statement closing procedures. Final results may differ from these preliminary unaudited estimates.